Exhibit 99.1

FORM 53-901F

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER

SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)

AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

Item 1. REPORTING ISSUER

Cardiome Pharma Corp.

6190 Agronomy Road, 6^th Floor

Vancouver, BC V6T 1Z3

Item 2. DATE OF MATERIAL CHANGE

February 19, 2007

Item 3. PRESS RELEASE

February 19, 2007 - Vancouver, British Columbia

Item 4. SUMMARY OF MATERIAL CHANGE

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. today announced that the New Drug Application (NDA) for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, has been accepted for review by the U.S. Food & Drug Administration (FDA).

Item 5. FULL DESCRIPTION OF MATERIAL CHANGE

See attached press release

Item 6. RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

Not Applicable.

Item 7. OMITTED INFORMATION

Not Applicable.

Item 8. SENIOR OFFICER

Name:Curtis Sikorsky

Title:Chief Financial Officer

Phone No.:604-677-6905

Item 9. STATEMENT OF SENIOR OFFICER

The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, British Columbia, this 19th day of February, 2007.

CARDIOME PHARMA CORP.
Per:	“Curtis Sikorsky”
	Curtis Sikorsky,
	Chief Financial Officer

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.